Immutep’s Eftilagimod Alfa Data on Soft Tissue Sarcoma Set for ESMO 2026
Event summary
- Immutep’s abstract on EFTISARC-NEO Phase II trial accepted for ESMO Congress 2026.
- Study evaluates eftilagimod alfa in combination with pembrolizumab and radiotherapy for soft tissue sarcoma (STS).
- Presentation scheduled as an ePoster (#3788eP) during the October 23–27 event in Madrid.
- First author is Pawel Teterycz, M.D., from MSCNRIO in Warsaw, Poland.
The big picture
Immutep’s presentation at ESMO 2026 underscores the growing focus on combination immunotherapies for rare cancers. The trial’s emphasis on HRQoL aligns with broader industry trends prioritizing patient-centric outcomes in oncology. Success here could bolster Immutep’s late-stage pipeline and investor confidence amid a crowded immunotherapy landscape.
What we're watching
- Clinical Efficacy
- How the HRQoL data from EFTISARC-NEO will influence perceptions of efti’s therapeutic potential in STS.
- Regulatory Pathway
- Whether positive results could accelerate Immutep’s regulatory discussions for eftilagimod alfa.
- Market Positioning
- The pace at which Immutep can differentiate itself in the competitive immunotherapy space.
Related topics